Clinical trials
Completed Triple Negative Breast Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
212 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 9 |
| 2010 | 12 |
| 2011 | 11 |
| 2012 | 12 |
| 2013 | 10 |
| 2014 | 14 |
| 2015 | 16 |
| 2016 | 20 |
| 2017 | 33 |
| 2018 | 22 |
| 2019 | 17 |
| 2020 | 8 |
| 2021 | 12 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 212 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 17 |
| Novartis Pharmaceuticals | 9 |
| M.D. Anderson Cancer Center | 8 |
| Hoffmann-La Roche | 6 |
| AstraZeneca | 5 |
| City of Hope Medical Center | 5 |
| Merck Sharp & Dohme LLC | 5 |
| Mayo Clinic | 4 |
| Sanofi | 4 |
| Vanderbilt-Ingram Cancer Center | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 212 |
| Breast Neoplasms | 107 |
| Carcinoma, Non-Small-Cell Lung | 47 |
| Ovarian Neoplasms | 37 |
| Pancreatic Neoplasms | 26 |
| Carcinoma, Renal Cell | 24 |
| Melanoma | 22 |
| Colorectal Neoplasms | 21 |
| Neoplasm Metastasis | 21 |
| Neoplasms | 21 |
Trials
Showing 1 to 25 of 212. Each trial links to its page on Pharma Observatory.
112 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.